לויטרה 10 מ"ג טבליות מסיסות ישראל - עברית - Ministry of Health

לויטרה 10 מ"ג טבליות מסיסות

bayer israel ltd - vardenafil as hydrochloride trihydrate 10 mg - tablets orodispersible - vardenafil - treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. in order for levitra to be effective, sexual stimulation is required. not indicated for use by women.

לויטרה 10 מג טבליות מסיסות ישראל - עברית - Ministry of Health

לויטרה 10 מג טבליות מסיסות

bayer israel ltd - vardenafil as hydrochloride trihydrate - טבליות מסיסות בפה - vardenafil as hydrochloride trihydrate 10 mg - vardenafil - vardenafil - treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. in order for levitra to be effective, sexual stimulation is required. not indicated for use by women.

גמציטבין מדאק 1500 מג ישראל - עברית - Ministry of Health

גמציטבין מדאק 1500 מג

tzamal bio-pharma ltd - gemcitabine as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can bee considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum - based, first- line therapy. gemcitabine in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemothe

ג'מסיטאבין אקטביס 200 מ"ג/בקבוקון ישראל - עברית - Ministry of Health

ג'מסיטאבין אקטביס 200 מ"ג/בקבוקון

devries & co. ltd - gemcitabine 200 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap

ג'מסיטאבין אקטביס 1000 מ"ג/בקבוקון ישראל - עברית - Ministry of Health

ג'מסיטאבין אקטביס 1000 מ"ג/בקבוקון

devries & co. ltd - gemcitabine 1000 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap

ז'בלור ישראל - עברית - Ministry of Health

ז'בלור

perrigo israel agencies ltd - vinflunine ditartrate - תרכיז להכנת תמיסה לאינפוזיה - vinflunine ditartrate 25 mg/ml - vinflunine - vinflunine - javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinium-containing regimen. efficacy and safety of vinflunine have not been studied in patients with performance status ?2.

רגולין וטרינרי ישראל - עברית - Ministry of Health

רגולין וטרינרי

romat ltd - melatonin 18 mg - implant for injection - improvment of the reproductive performance of the sheep.

טייקרב ישראל - עברית - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.